Skip to content

Effects of Nocturnal Non-invasive Ventilation on Energy Expenditure in Patients With Severe Chronic Obstructive Pulmonary Disease

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01961245
Enrollment
85
Registered
2013-10-11
Start date
2013-12-31
Completion date
2019-12-31
Last updated
2019-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease, Energy Expenditure, Non-invasive Ventilation, Pulmonary Rehabilitation

Brief summary

It has been shown, that in patients with very severe chronic obstructive pulmonary disease (COPD) the additional use of non-invasive ventilation during pulmonary rehabilitation (PR) may enhance the benefits of PR. It is assumed that the non-invasive ventilation techniques provides a better recovery of the respiratory pump during the night. If non-invasive ventilation also decreases the metabolic demands during night is unknown and is aim of this study. During a 3 week inpatient pulmonary rehabilitation program a total of 85 patients with chronic obstructive pulmonary disease stage IV will be recruited for this study. There will be a 4:1 distribution into 2 groups. 68 patients with an indication for the use of a non-invasive ventilation will be involved in the intervention group where non-invasive ventilation will be initialized. 17 patients with chronic obstructive pulmonary disease stage IV without an indication for the use of non-invasive ventilation will be involved in a control group to detect the changes in nocturnal energy expenditure produced by pulmonary rehabilitation alone. All outcome measurements will be performed during day 1-3 and will be repeated after 12 days (with or without non-invasive ventilation) at day 15-17 of the pulmonary rehabilitation program. A sub-trial of this study is to validate night movement accuracy of the Dynaport activity monitor with the observations made by a night-vision camera in the sleep lab. This will be performed in study participants as well as in healthy volunteers.

Interventions

patients will undergo a non-invasive ventilation during the night

Sponsors

Schön Klinik Berchtesgadener Land
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

for Intervention group: * chronic obstructive pulmonary disease stage IV * indication for the use of a nocturnal non-invasive ventilation (according to the German guidelines Schoenhofer et al. 2008) * patient has not yet used non-invasive ventilation at all or inadequately (less than 3 hours per day)

Exclusion criteria

for Intervention group: * acute exacerbation of chronic obstructive pulmonary disease * severe heart failure * body-mass-index \>35 m²/kg * fever Inclusion Criteria for control group: * chronic obstructive pulmonary disease stage IV (- healthy volunteers are also eligible for the sub-trial of this study to validate night movement accuracy of an activity monitor)

Design outcomes

Primary

MeasureTime frameDescription
energy expenditure during nightday 1-3 and day 14-16energy expenditure will be assessed by Sensewear Armband

Secondary

MeasureTime frameDescription
energy expenditure during dayday 1-3 and day 14-16energy expenditure will be assessed by SenseWear Armband
lung functionday 1-3 and day 14-16measured by a bodyplethysmograph
sleep qualityday 1-3 and day 14-16measured by Severe Respiratory Insufficiency Questionnaire
arterial pressure of carbon dioxide during nightday 1-3 and day 14-16measured transcutaneously by a Sentec device
movement activity during the nightday 1night movement activity will be measured in a subgroup with the Dynaport device

Countries

Germany

Contacts

Primary ContactKlaus Kenn, Dr.
kkenn@schoen-kliniken.de+49 8652 931451
Backup ContactRainer Gloeckl
rgloeckl@schoen-kliniken.de+49 8652 931630

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026